+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
UCB (Union chimique belge) - logo

UCB is a global biopharmaceutical company that focuses on neurology and immunology. The company’s core products are Cimzia, Vimpat, Neupro, Keppra and Briviact, and they are also preparing the launch of a potential medicine to help patients with osteoporosis. It offers products for the treatment of central nervous system disorders, allergy and respiratory diseases, and immune and inflammatory disorders. UCB employs over 7,000 people and is based in Brussels, Belgium.

Hypoprothrombinemia Treatment Market - Global Forecast to 2030 - Product Thumbnail Image

Hypoprothrombinemia Treatment Market - Global Forecast to 2030

  • Report
  • August 2025
  • 187 Pages
  • Global
From
Osteogenesis Imperfecta (OI) - Pipeline Insight, 2025 - Product Thumbnail Image

Osteogenesis Imperfecta (OI) - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
From
Nootropics Market Report 2026 - Product Thumbnail Image

Nootropics Market Report 2026

  • Report
  • February 2026
  • 250 Pages
  • Global
From
From
Biologics Market - Forecasts from 2024 to 2029 - Product Thumbnail Image

Biologics Market - Forecasts from 2024 to 2029

  • Report
  • April 2024
  • 121 Pages
  • Global
From
From
Tau Protein Inhibitors - Pipeline Insight, 2025 - Product Thumbnail Image

Tau Protein Inhibitors - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
CARTISTEM Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

CARTISTEM Drug Insight and Market Forecast - 2032

  • Report
  • November 2023
  • 30 Pages
  • Global
From
From
From
Loading Indicator